A Phase 2 interventional study of Nivolumab and Ipilimumab in Advanced Cancer, sponsored by Bristol-Myers Squibb. Completed at 32 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-12-19.
Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to test the effectiveness and safety of various nivolumab combinations compared to nivolumab and ipilimumab in participants with advanced kidney cancer
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol defined inclusion/exclusion criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Nivolumab + Ipilimumab
Biological: Nivolumab · Biological: Ipilimumab
Nivolumab + Relatlimab
Biological: Nivolumab · Biological: Relatlimab
Nivolumab + BMS-986205
Biological: Nivolumab · Drug: BMS-986205
Nivolumab + BMS-813160 (CCR2/5 dual antagonist)
Biological: Nivolumab · Drug: BMS-813160
Specified Dose on Specified Days
Also known as: Opdivo, BMS-936558
Specified Dose on Specified Days
Also known as: BMS-734016, Yervoy
Specified Dose on Specified Days
Also known as: BMS-986016
Specified Dose on Specified Days
Specified Dose on Specified Days
Objective Response Rate (ORR) Per Investigator
ORR is percent of participants whose best overall response (BOR) is complete response (CR) or partial response (PR). BOR is the best response from the start of the study treatment until objectively documented progression per RECIST v1.1 or subsequent anticancer therapy, whichever occurs first. For participants who received re-treatment or were re-randomized, the re-treatment and re-randomized therapies were considered subsequent anticancer therapy. CR is the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) have reduction in short axis to \<10 mm. PR is at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. The Response Evaluation Criteria in Solid Tumors (RECIST) is a standard way to measure the response of a tumor to treatment. CR+PR, confidence interval based on Clopper and Pearson method.
Time frame: From first dose of study treatment until progression or subsequent anticancer therapy, whichever occurs first (assessed up to approximately 247 weeks)
Median Duration of Response (DOR) Per Investigator
Duration of Response is defined as the time between the date of first response and the date of first documented disease progression as determined by RECIST 1.1 or death due to any cause (death occurring after re-treatment or randomization to new combination treatment was not considered), whichever occurred first. Complete Response (CR) is the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Partial Response (PR) is at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Median computed using Kaplan -Meier method
Time frame: From first dose to the date of first documented disease progression or death due to any cause (assessed from an average of 22 weeks up to approximately 247 weeks)
Progression Free Survival Rate (PFSR) at 24 Weeks.
The PFSR at 24 weeks is defined as the proportion of treated participants remaining progression free and surviving at 24 weeks since the first dosing date. Progressive Disease (PD) is at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression). Point estimates are derived from Kaplan-Meier analyses, the 95% CIs are derived from Greenwood formula
Time frame: 24 weeks after first treatment dose.
Number of Participants With Adverse Events (AEs)
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.
Time frame: From first dose to 100 days after last dose of study therapy (assessed up to approximately 118 weeks)
Number of Participants With Serious Adverse Events (SAEs)
Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening (defined as an event in which the participant was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe), requires inpatient hospitalization or causes prolongation of existing hospitalization
Time frame: From first dose to 100 days after last dose of study therapy (assessed up to approximately 118 weeks)
Number of Participants With Adverse Events (AEs) Leading to Discontinuation
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.
Time frame: From first dose to 100 days after last dose of study therapy (assessed up to approximately 118 weeks)
Number of Participants Who Died
Death is defined as the cessation of all vital functions of the body including the heartbeat, brain activity (including the brain stem), and breathing.
Time frame: From first dose to 100 days after last dose of study therapy (assessed up to approximately 118 weeks)
Number of Participants With Abnormal Thyroid Test Results - Track 1
The number of participants with laboratory abnormalities in specific thyroid tests based on SI conventional units. TSH = Thyroid Stimulating Hormone LLN = Lower Limit of Normal ULN = Upper Limit of Normal.
Time frame: From first dose to 30 days after last dose of study therapy (approximately 108 weeks)
Number of Participants With Abnormal Thyroid Test Results - Track 2
The number of participants with laboratory abnormalities in specific thyroid tests based on SI conventional units. TSH = Thyroid Stimulating Hormone LLN = Lower Limit of Normal ULN = Upper Limit of Normal
Time frame: From first dose to 30 days after last dose of study therapy (approximately 108 weeks)
Number of Participants With Abnormal Hepatic Test Results - Track 1
The number of participants with laboratory abnormalities in specific liver tests based on SI conventional units. ALT = Alanine Aminotransferase AST = Aspartate Aminotransferase ULN = Upper Limit of Normal
Time frame: From first dose to 30 days after last dose of study therapy (approximately 108 weeks)
Number of Participants With Abnormal Hepatic Test Results - Track 2
The number of participants with laboratory abnormalities in specific liver tests based on SI conventional units. ALT = Alanine Aminotransferase AST = Aspartate Aminotransferase ULN = Upper Limit of Normal
Time frame: From first dose to 30 days after last dose of study therapy (approximately 108 weeks)
| Milestone | Arm 1: Nivolumab Plus Ipilimumab (BMS-734016) | Arm 2: Nivolumab Plus Relatlimab (BMS-986016) | Arm 3: Nivolumab Plus BMS-986205 | Arm 4: Nivolumab Plus BMS-813160 150 mg | Arm 5: Nivolumab Plus BMS-813160 300mg |
|---|---|---|---|---|---|
| Started | 65 | 56 | 26 | 17 | 18 |
| Completed | 65 | 55 | 25 | 17 | 16 |
| Not completed | 0 | 1 | 1 | 0 | 2 |
| Withdrew: Other reasons | 0 | 1 | 0 | 0 | 1 |
| Withdrew: Participant withdrew consent | 0 | 0 | 1 | 0 | 1 |
| Milestone | Arm 1: Nivolumab Plus Ipilimumab (BMS-734016) | Arm 2: Nivolumab Plus Relatlimab (BMS-986016) | Arm 3: Nivolumab Plus BMS-986205 | Arm 4: Nivolumab Plus BMS-813160 150 mg | Arm 5: Nivolumab Plus BMS-813160 300mg |
|---|---|---|---|---|---|
| Started | 30 | 30 | 0 | 0 | 0 |
| Re-randomized to track 2 | 5 | 6 | 0 | 0 | 0 |
| Completed | 7 | 8 | 0 | 0 | 0 |
| Not completed | 23 | 22 | 0 | 0 | 0 |
| Withdrew: Disease progression | 15 | 17 | 0 | 0 | 0 |
| Withdrew: Adverse event unrelated to study drug | 1 | 1 | 0 | 0 | 0 |
| Withdrew: Study drug toxicity | 5 | 3 | 0 | 0 | 0 |
| Withdrew: Participant requested to discontinue study treatment | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Administrative reason by sponsor | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Participant no longer met study criteria | 1 | 0 | 0 | 0 | 0 |
| Milestone | Arm 1: Nivolumab Plus Ipilimumab (BMS-734016) | Arm 2: Nivolumab Plus Relatlimab (BMS-986016) | Arm 3: Nivolumab Plus BMS-986205 | Arm 4: Nivolumab Plus BMS-813160 150 mg | Arm 5: Nivolumab Plus BMS-813160 300mg |
|---|---|---|---|---|---|
| Started | 46 | 32 | 31 | 21 | 22 |
| No pre-randomization | 35 | 25 | 25 | 17 | 16 |
| Re-randomized from track 1 nivolumab + relatlimab | 2 | 0 | 2 | 1 | 1 |
| Re-randomized from track 1 nivolumab + ipilimumab | 0 | 3 | 1 | 1 | 0 |
| Re-randomized from track 2 nivolumab + relatlimab | 7 | 0 | 2 | 0 | 1 |
| Re-randomized from track 2 nivolumab + bms986205 | 2 | 2 | 0 | 1 | 2 |
| Previously un-treated but re-randomized | 0 | 0 | 0 | 1 | 0 |
| Re-randomized from track 2 nivolumab + ipilimumab | 0 | 2 | 1 | 0 | 2 |
| Completed | 4 | 3 | 1 | 1 | 1 |
| Not completed | 42 | 29 | 30 | 20 | 21 |
| Withdrew: Disease progression | 33 | 26 | 19 | 16 | 15 |
| Withdrew: Adverse event unrelated to study drug | 4 | 0 | 0 | 1 | 1 |
| Withdrew: Death | 0 | 0 | 1 | 0 | 1 |
| Withdrew: Study drug toxicity | 4 | 1 | 4 | 1 | 0 |
| Withdrew: Participant requested to discontinue study treatment | 0 | 0 | 2 | 1 | 2 |
| Withdrew: Participant withdrew consent | 1 | 2 | 3 | 1 | 1 |
| Withdrew: Other reasons | 0 | 0 | 1 | 0 | 1 |
ORR is percent of participants whose best overall response (BOR) is complete response (CR) or partial response (PR). BOR is the best response from the start of the study treatment until objectively documented progression per RECIST v1.1 or subsequent anticancer therapy, whichever occurs first. For participants who received re-treatment or were re-randomized, the re-treatment and re-randomized therapies were considered subsequent anticancer therapy. CR is the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) have reduction in short axis to \<10 mm. PR is at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. The Response Evaluation Criteria in Solid Tumors (RECIST) is a standard way to measure the response of a tumor to treatment. CR+PR, confidence interval based on Clopper and Pearson method.
| Percent of participants | Arm 1: Nivolumab Plus Ipilimumab (BMS-734016) | Arm 2: Nivolumab Plus Relatlimab (BMS-986016) | Arm 3: Nivolumab Plus BMS-986205 | Arm 4: Nivolumab Plus BMS-813160 150 mg | Arm 5: Nivolumab Plus BMS-813160 300mg |
|---|---|---|---|---|---|
| Track 1 | 20 (7.7 to 38.6) | 30 (14.7 to 49.4) | — | — | — |
| Track 2 | 17.4 (7.8 to 31.4) | 3.1 (0.1 to 16.2) | 3.2 (0.1 to 16.7) | 9.5 (1.2 to 30.4) | 0.0 (0.0 to 15.4) |
Duration of Response is defined as the time between the date of first response and the date of first documented disease progression as determined by RECIST 1.1 or death due to any cause (death occurring after re-treatment or randomization to new combination treatment was not considered), whichever occurred first. Complete Response (CR) is the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Partial Response (PR) is at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Median computed using Kaplan -Meier method
| Weeks | Arm 1: Nivolumab Plus Ipilimumab (BMS-734016) | Arm 2: Nivolumab Plus Relatlimab (BMS-986016) | Arm 3: Nivolumab Plus BMS-986205 | Arm 4: Nivolumab Plus BMS-813160 150 mg | Arm 5: Nivolumab Plus BMS-813160 300mg |
|---|---|---|---|---|---|
| Track 1 | NA (33.4 to 139.9) | 32.57 (0.1 to 52.6) | — | — | — |
| Track 2 | 68.00 (0.1 to 117.6) | 99.4 (99.4 to 99.4) | NA (NA to NA) | NA (NA to NA) | — |
The PFSR at 24 weeks is defined as the proportion of treated participants remaining progression free and surviving at 24 weeks since the first dosing date. Progressive Disease (PD) is at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression). Point estimates are derived from Kaplan-Meier analyses, the 95% CIs are derived from Greenwood formula
| Proportion of participants | Arm 1: Nivolumab Plus Ipilimumab (BMS-734016) | Arm 2: Nivolumab Plus Relatlimab (BMS-986016) | Arm 3: Nivolumab Plus BMS-986205 | Arm 4: Nivolumab Plus BMS-813160 150 mg | Arm 5: Nivolumab Plus BMS-813160 300mg |
|---|---|---|---|---|---|
| Track 1 | 0.491 (0.294 to 0.661) | 0.429 (0.246 to 0.600) | — | — | — |
| Track 2 | 0.432 (0.277 to 0.577) | 0.194 (0.079 to 0.346) | 0.278 (0.118 to 0.464) | 0.468 (0.237 to 0.670) | NA (NA to NA) |
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.
| Participants | Arm 1: Nivolumab Plus Ipilimumab (BMS-734016) | Arm 2: Nivolumab Plus Relatlimab (BMS-986016) | Arm 3: Nivolumab Plus BMS-986205 | Arm 4: Nivolumab Plus BMS-813160 150 mg | Arm 5: Nivolumab Plus BMS-813160 300mg |
|---|---|---|---|---|---|
| Track 1 | 29 | 30 | — | — | — |
| Track 2 | 45 | 32 | 31 | 19 | 21 |
Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening (defined as an event in which the participant was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe), requires inpatient hospitalization or causes prolongation of existing hospitalization
| Participants | Arm 1: Nivolumab Plus Ipilimumab (BMS-734016) | Arm 2: Nivolumab Plus Relatlimab (BMS-986016) | Arm 3: Nivolumab Plus BMS-986205 | Arm 4: Nivolumab Plus BMS-813160 150 mg | Arm 5: Nivolumab Plus BMS-813160 300mg |
|---|---|---|---|---|---|
| Track 1 | 17 | 15 | — | — | — |
| Track 2 | 28 | 16 | 16 | 9 | 15 |
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.
| Participants | Arm 1: Nivolumab Plus Ipilimumab (BMS-734016) | Arm 2: Nivolumab Plus Relatlimab (BMS-986016) | Arm 3: Nivolumab Plus BMS-986205 | Arm 4: Nivolumab Plus BMS-813160 150 mg | Arm 5: Nivolumab Plus BMS-813160 300mg |
|---|---|---|---|---|---|
| Track 1 | 7 | 7 | — | — | — |
| Track 2 | 10 | 3 | 6 | 2 | 4 |
Death is defined as the cessation of all vital functions of the body including the heartbeat, brain activity (including the brain stem), and breathing.
| Participants | Arm 1: Nivolumab Plus Ipilimumab (BMS-734016) | Arm 2: Nivolumab Plus Relatlimab (BMS-986016) | Arm 3: Nivolumab Plus BMS-986205 | Arm 4: Nivolumab Plus BMS-813160 150 mg | Arm 5: Nivolumab Plus BMS-813160 300mg |
|---|---|---|---|---|---|
| Track 1 | 12 | 15 | — | — | — |
| Track 2 | 27 | 17 | 13 | 10 | 13 |
The number of participants with laboratory abnormalities in specific thyroid tests based on SI conventional units. TSH = Thyroid Stimulating Hormone LLN = Lower Limit of Normal ULN = Upper Limit of Normal.
| Participants | Arm 1: Nivolumab Plus Ipilimumab (BMS-734016) | Arm 2: Nivolumab Plus Relatlimab (BMS-986016) | Arm 3: Nivolumab Plus BMS-986205 | Arm 4: Nivolumab Plus BMS-813160 150 mg | Arm 5: Nivolumab Plus BMS-813160 300mg |
|---|---|---|---|---|---|
| TSH > ULN | 8 | 8 | 0 | 0 | 0 |
| TSH > ULN WITH TSH <= ULN AT BASELINE | 5 | 8 | 0 | 0 | 0 |
| TSH >ULN WITH ATLEAST ONE FT3/FT4 TEST VALUE <LLN | 3 | 3 | 0 | 0 | 0 |
| TSH >ULN WITH ALL OTHER FT3/FT4 TEST VALUES >= LLN | 3 | 2 | 0 | 0 | 0 |
| TSH > ULN WITH FT3/FT4 TEST MISSING | 2 | 3 | 0 | 0 | 0 |
| TSH < LLN | 10 | 5 | 0 | 0 | 0 |
| TSH <LLN WITH TSH >= LLN AT BASELINE | 9 | 5 | 0 | 0 | 0 |
| TSH <LLN WITH ATLEAST ONE FT3/FT4 TEST VALUE > ULN | 3 | 0 | 0 | 0 | 0 |
| TSH <LLN WITH ALL OTHER FT3/FT4 TEST VALUES <= ULN | 2 | 1 | 0 | 0 | 0 |
| TSH < LLN WITH FT3/FT4 TEST MISSING | 5 | 4 | 0 | 0 | 0 |
The number of participants with laboratory abnormalities in specific thyroid tests based on SI conventional units. TSH = Thyroid Stimulating Hormone LLN = Lower Limit of Normal ULN = Upper Limit of Normal
| Participants | Arm 1: Nivolumab Plus Ipilimumab (BMS-734016) | Arm 2: Nivolumab Plus Relatlimab (BMS-986016) | Arm 3: Nivolumab Plus BMS-986205 | Arm 4: Nivolumab Plus BMS-813160 150 mg | Arm 5: Nivolumab Plus BMS-813160 300mg |
|---|---|---|---|---|---|
| TSH > ULN | 14 | 14 | 6 | 3 | 4 |
| TSH > ULN WITH TSH <= ULN AT BASELINE | 8 | 6 | 3 | 2 | 2 |
| TSH >ULN WITH ATLEAST ONE FT3/FT4 TEST VALUE <LLN | 5 | 3 | 1 | 1 | 0 |
| TSH >ULN WITH ALL OTHER FT3/FT4 TEST VALUES >= LLN | 5 | 4 | 3 | 2 | 3 |
| TSH > ULN WITH FT3/FT4 TEST MISSING | 4 | 7 | 2 | 0 | 1 |
| TSH < LLN | 4 | 5 | 2 | 2 | 1 |
| TSH <LLN WITH TSH >= LLN AT BASELINE | 2 | 4 | 1 | 2 | 1 |
| TSH <LLN WITH ATLEAST ONE FT3/FT4 TEST VALUE > ULN | 1 | 0 | 1 | 1 | 0 |
| TSH <LLN WITH ALL OTHER FT3/FT4 TEST VALUES <= ULN | 0 | 3 | 0 | 0 | 0 |
| TSH < LLN WITH FT3/FT4 TEST MISSING | 3 | 2 | 1 | 1 | 1 |
The number of participants with laboratory abnormalities in specific liver tests based on SI conventional units. ALT = Alanine Aminotransferase AST = Aspartate Aminotransferase ULN = Upper Limit of Normal
| Participants | Arm 1: Nivolumab Plus Ipilimumab (BMS-734016) | Arm 2: Nivolumab Plus Relatlimab (BMS-986016) | Arm 3: Nivolumab Plus BMS-986205 | Arm 4: Nivolumab Plus BMS-813160 150 mg | Arm 5: Nivolumab Plus BMS-813160 300mg |
|---|---|---|---|---|---|
| ALT OR AST > 3XULN | 2 | 4 | 0 | 0 | 0 |
| ALT OR AST> 5XULN | 1 | 2 | 0 | 0 | 0 |
| ALT OR AST> 10XULN | 0 | 0 | 00 | 0 | 0 |
| ALT OR AST > 20XULN | 0 | 0 | 0 | 0 | 0 |
| TOTAL BILIRUBIN > 2XULN | 0 | 0 | 0 | 0 | 0 |
| ALT/AST ELEV>3XULN;TOTAL BILIRUBIN>2XULN IN 1 DAY | 0 | 0 | 0 | 0 | 0 |
| ALT/AST ELEV>3XULN;TOTAL BILIRUBIN>2XULN IN 30 DAYS | 0 | 0 | 0 | 0 | 0 |
The number of participants with laboratory abnormalities in specific liver tests based on SI conventional units. ALT = Alanine Aminotransferase AST = Aspartate Aminotransferase ULN = Upper Limit of Normal
| Participants | Arm 1: Nivolumab Plus Ipilimumab (BMS-734016) | Arm 2: Nivolumab Plus Relatlimab (BMS-986016) | Arm 3: Nivolumab Plus BMS-986205 | Arm 4: Nivolumab Plus BMS-813160 150 mg | Arm 5: Nivolumab Plus BMS-813160 300mg |
|---|---|---|---|---|---|
| ALT OR AST > 3XULN | 3 | 1 | 1 | 0 | 0 |
| ALT OR AST> 5XULN | 2 | 0 | 1 | 0 | 0 |
| ALT OR AST> 10XULN | 0 | 0 | 0 | 0 | 0 |
| ALT OR AST > 20XULN | 0 | 0 | 0 | 0 | 0 |
| TOTAL BILIRUBIN > 2XULN | 2 | 0 | 0 | 0 | 0 |
| ALT/AST ELEV>3XULN;TOTAL BILIRUBIN>2XULN IN 1 DAY | 0 | 0 | 0 | 0 | 0 |
| ALT/AST ELEV>3XULN;TOTAL BILIRUBIN>2XULN IN 30 DAYS | 0 | 0 | 0 | 0 | 0 |
Collected over Participants were assessed for All-Cause Mortality from the date of their randomization until study completion (assessed up to approximately 250 weeks). SAEs and Other AEs were assessed from first dose to 100 days after last dose of study therapy (assessed up to approximately 118 weeks).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Track 1: Nivolumab Plus Ipilimumab (BMS-734016) | 12/30 (40%) | 17/30 (56.7%) | 28/30 (93.3%) |
| Track 1: Nivolumab Plus Relatlimab (BMS-986016) | 15/31 (48.4%) | 15/30 (50%) | 29/30 (96.7%) |
| Track 2: Nivolumab Plus Ipilimumab (BMS-734016) | 27/46 (58.7%) | 28/46 (60.9%) | 42/46 (91.3%) |
| Track 2: Nivolumab Plus Relatlimab (BMS-986016) | 17/32 (53.1%) | 16/32 (50%) | 31/32 (96.9%) |
| Track 2: Nivolumab Plus BMS-986205 | 13/32 (40.6%) | 16/31 (51.6%) | 29/31 (93.5%) |
| Track 2: Nivolumab Plus BMS-813160 150 mg | 10/21 (47.6%) | 9/21 (42.9%) | 18/21 (85.7%) |
| Track 2: Nivolumab Plus BMS-813160 300 mg | 13/24 (54.2%) | 15/22 (68.2%) | 17/22 (77.3%) |
| Event | Track 1: Nivolumab Plus Ipilimumab (BMS-734016) | Track 1: Nivolumab Plus Relatlimab (BMS-986016) | Track 2: Nivolumab Plus Ipilimumab (BMS-734016) | Track 2: Nivolumab Plus Relatlimab (BMS-986016) | Track 2: Nivolumab Plus BMS-986205 | Track 2: Nivolumab Plus BMS-813160 150 mg | Track 2: Nivolumab Plus BMS-813160 300 mg |
|---|---|---|---|---|---|---|---|
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/30 | 5/30 | 6/46 | 5/32 | 3/31 | 1/21 | 4/22 |
| PneumoniaInfections and infestations | 4/30 | 0/30 | 0/46 | 3/32 | 2/31 | 0/21 | 2/22 |
| HypercalcaemiaMetabolism and nutrition disorders | 2/30 | 3/30 | 2/46 | 0/32 | 1/31 | 0/21 | 0/22 |
| Acute kidney injuryRenal and urinary disorders | 0/30 | 0/30 | 0/46 | 0/32 | 0/31 | 2/21 | 1/22 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/30 | 0/30 | 1/46 | 1/32 | 2/31 | 2/21 | 0/22 |
| VomitingGastrointestinal disorders | 0/30 | 2/30 | 0/46 | 0/32 | 1/31 | 0/21 | 0/22 |
| DehydrationMetabolism and nutrition disorders | 2/30 | 0/30 | 0/46 | 0/32 | 0/31 | 0/21 | 0/22 |
| Spinal cord compressionNervous system disorders | 0/30 | 2/30 | 1/46 | 1/32 | 1/31 | 0/21 | 0/22 |
| Wound dehiscenceInjury, poisoning and procedural complications | 0/30 | 0/30 | 0/46 | 1/32 | 2/31 | 0/21 | 0/22 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 1/30 | 0/30 | 0/46 | 1/32 | 2/31 | 0/21 | 0/22 |
| Event | Track 1: Nivolumab Plus Ipilimumab (BMS-734016) | Track 1: Nivolumab Plus Relatlimab (BMS-986016) | Track 2: Nivolumab Plus Ipilimumab (BMS-734016) | Track 2: Nivolumab Plus Relatlimab (BMS-986016) | Track 2: Nivolumab Plus BMS-986205 | Track 2: Nivolumab Plus BMS-813160 150 mg | Track 2: Nivolumab Plus BMS-813160 300 mg |
|---|---|---|---|---|---|---|---|
| FatigueGeneral disorders | 9/30 | 13/30 | 15/46 | 11/32 | 8/31 | 7/21 | 6/22 |
| ConstipationGastrointestinal disorders | 3/30 | 8/30 | 5/46 | 12/32 | 6/31 | 2/21 | 2/22 |
| CoughRespiratory, thoracic and mediastinal disorders | 11/30 | 6/30 | 10/46 | 8/32 | 6/31 | 6/21 | 2/22 |
| NauseaGastrointestinal disorders | 10/30 | 7/30 | 14/46 | 8/32 | 8/31 | 6/21 | 4/22 |
| HeadacheNervous system disorders | 4/30 | 10/30 | 5/46 | 1/32 | 2/31 | 3/21 | 3/22 |
| PruritusSkin and subcutaneous tissue disorders | 10/30 | 6/30 | 10/46 | 8/32 | 2/31 | 3/21 | 1/22 |
| DiarrhoeaGastrointestinal disorders | 6/30 | 9/30 | 14/46 | 7/32 | 5/31 | 6/21 | 1/22 |
| AnaemiaBlood and lymphatic system disorders | 8/30 | 5/30 | 8/46 | 4/32 | 4/31 | 2/21 | 2/22 |
| RashSkin and subcutaneous tissue disorders | 8/30 | 7/30 | 12/46 | 7/32 | 3/31 | 4/21 | 2/22 |
| Decreased appetiteMetabolism and nutrition disorders | 5/30 | 5/30 | 12/46 | 8/32 | 4/31 | 5/21 | 3/22 |
Arms 1 and 2 take into account both Track 1 and Track 2 participants as well as those rerandomized to the respective arms in Track 2.
| Age, Categorical(Participants) | Arm 1: Nivolumab Plus Ipilimumab (BMS-734016) | Arm 2: Nivolumab Plus Relatlimab (BMS-986016) | Arm 3: Nivolumab Plus BMS-986205 | Arm 4: Nivolumab Plus BMS-813160 150 mg | Arm 5: Nivolumab Plus BMS-813160 300mg | Total |
|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 40 | 41 | 16 | 12 | 11 | 120 |
| >=65 years | 25 | 15 | 10 | 5 | 7 | 62 |
| Sex: Female, Male(Participants) | Arm 1: Nivolumab Plus Ipilimumab (BMS-734016) | Arm 2: Nivolumab Plus Relatlimab (BMS-986016) | Arm 3: Nivolumab Plus BMS-986205 | Arm 4: Nivolumab Plus BMS-813160 150 mg | Arm 5: Nivolumab Plus BMS-813160 300mg | Total |
|---|---|---|---|---|---|---|
| Female | 14 | 16 | 6 | 4 | 9 | 49 |
| Male | 51 | 40 | 20 | 13 | 9 | 133 |
| Ethnicity (NIH/OMB)(Participants) | Arm 1: Nivolumab Plus Ipilimumab (BMS-734016) | Arm 2: Nivolumab Plus Relatlimab (BMS-986016) | Arm 3: Nivolumab Plus BMS-986205 | Arm 4: Nivolumab Plus BMS-813160 150 mg | Arm 5: Nivolumab Plus BMS-813160 300mg | Total |
|---|---|---|---|---|---|---|
| Track 2 — Hispanic or Latino | 3 | 2 | 2 | 1 | 0 | 8 |
| Track 2 — Not Hispanic or Latino | 37 | 34 | 19 | 12 | 10 | 112 |
| Track 2 — Unknown or Not Reported | 25 | 20 | 5 | 4 | 8 | 62 |
| Race/Ethnicity, Customized(Participants) | Arm 1: Nivolumab Plus Ipilimumab (BMS-734016) | Arm 2: Nivolumab Plus Relatlimab (BMS-986016) | Arm 3: Nivolumab Plus BMS-986205 | Arm 4: Nivolumab Plus BMS-813160 150 mg | Arm 5: Nivolumab Plus BMS-813160 300mg | Total |
|---|---|---|---|---|---|---|
| White | 62 | 52 | 23 | 14 | 17 | 168 |
| Asian Indian | 1 | 0 | 0 | 0 | 0 | 1 |
| Chinese | 0 | 1 | 0 | 0 | 0 | 1 |
| Asian Other | 1 | 1 | 0 | 0 | 0 | 2 |
| Other | 1 | 2 | 2 | 2 | 0 | 7 |
| Black or African American | 0 | 0 | 1 | 1 | 1 | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Feb 2017 to primary completion in Nov 2021, 57 months.
Results were first posted in Dec 2022, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Relatlimab · Linrodostat · BMS-813160